Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


PBAC realigns biosim process

Posted 21 September 2019

In a ruling that should simplify its consideration of biosimilars, PBAC will no longer accept parallel processing submissions for the biological copies.

The declaration effectively eliminates any further poossibility of major submissions for biosimilars.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Six pharmas add generics
Most copy PBS listed drugs
Special Report
Aust Covid Vaccine Tracker
Live updates on frontrunners, local trials and deals
Top of the Hill
If only for a 2020 time machine
What would you do if you could start this year again?